Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Progen Pharmaceuticals.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Progen Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00130442
First received: August 12, 2005
Last updated: March 2, 2009
Last verified: March 2009
  Purpose

The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma.

PI-88 blocks new blood vessel growth in tumours (starves it of nutrients) and dacarbazine stops the cancer cells from growing. The results from this study will be analysed to see if it is worthwhile for the two drugs to be tested in future studies involving larger numbers of melanoma patients.


Condition Intervention Phase
Melanoma
Drug: PI-88 and dacarbazine
Drug: dacarbazine or DTIC
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Progen Pharmaceuticals:

Primary Outcome Measures:
  • The proportion of patients with objective response or stable disease (non-progression rate) after six treatment cycles [ Time Frame: after six treatment cycles ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Non-progression rate after two and four treatment cycles [ Time Frame: after two treatment cycles and after four treatment cycles ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: at the point of first radiological evidence of progressive disease ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: time from commencement to radiological evidence of progression ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: time to death and also at time-points 6 month and 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 118
Study Start Date: June 2005
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
PI-88 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
Drug: PI-88 and dacarbazine
190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
Active Comparator: 2
dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
Drug: dacarbazine or DTIC
intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle

Detailed Description:

Metastatic melanoma is a difficult-to-treat cancer for which available treatment options are limited and minimally effective. Dacarbazine is currently one of the standard chemotherapy drugs used for the treatment of metastatic melanoma. However, it is associated with low response rates (10-20%) and median survival of less than 12 months (6-11 months in most studies). PI-88 is an antiangiogenic and antimetastatic drug that has already shown some evidence of efficacy when used alone in an intermittent dosage regimen (4 consecutive days per week) in the treatment of patients with advanced melanoma. The FDA has designated PI-88 as an Orphan Drug for this indication, as well as for Stage III and high-risk stage II disease. The aim of this randomised pilot phase II trial is to determine whether PI-88 in combination with a standard regimen of dacarbazine (1000 mg/m2 every 3 weeks) should be considered for further investigation in a larger-scale trial.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven metastatic melanoma
  • Surgery not feasible or inappropriate
  • Measurable disease. Metastatic lesions must be measurable by magnetic resonance imaging (MRI) or computed tomography (CT) as defined in Response Evaluation Criteria in Solid Tumors (RECIST), and cutaneous lesions by physical examination.
  • Have voluntarily given written informed consent to participate in this study
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
  • Life expectancy at least 3 months
  • Neutrophil count > 1.5 x 10^9/L (1,500/mm3)
  • Platelet count > 100 x 10^9/L (100,000/mm3)
  • Acceptable liver function tests (see Exclusion Criteria for maximum allowable elevations of ALT, AST, ALP and LDH)
  • PT < 1.5 x upper limit of normal (ULN)
  • APTT < 1.5 x ULN
  • Creatinine clearance > 40 mL/min, calculated using the Cockcroft-Gault formula (if just below 40 mL/min, then GFR > 40 mL/min as determined by 24-hour urine collection)

Exclusion Criteria:

  • Current or history of central nervous system involvement, brain or meningeal metastases
  • Ocular melanoma
  • Clinically significant non-malignant disease
  • Prior or co-existent malignancies (other than stage I internal malignancy where treated and disease-free for > 5 years, non-melanomatous skin cancer or in situ cancer of the cervix)
  • Prior chemotherapy
  • Prior treatment with vaccines and/or biological response modifiers within the previous 4 weeks
  • Prior treatment with radiotherapy within the previous 4 weeks (local palliative radiotherapy is permitted)
  • Radiotherapy to > 30% of marrow-bearing bone within the previous 3 months
  • Major surgery within the past 4 weeks
  • Concomitant use of aspirin (> 150 mg/day), non-steroidal anti-inflammatory drugs (except specific COX-2 inhibitors), heparin, low molecular weight heparin, warfarin (> 1 mg/day) or anti-platelet drugs (abciximab, clopidogrel, dipyridamole, ticlopidine and tirofiban). Low-dose aspirin (≤ 150 mg/day) and low-dose warfarin (≤ 1 mg/day) are permitted as concomitant medications.
  • Heparin or low molecular weight heparin within the previous 2 weeks
  • History of acute or chronic gastrointestinal bleeding within the last 2 years, inflammatory bowel disease or other abnormal bleeding tendency
  • Patients at risk of bleeding due to open wounds or planned surgery
  • Bilirubin > 1.5 x ULN
  • AST or ALT > 3 x ULN unless patient has hepatic metastases
  • LDH > 2 x ULN
  • Alkaline phosphatase > 5 x ULN, unless patient has bone metastases
  • Myocardial infarction, stroke or congestive heart failure within the past 3 months
  • Women who are pregnant or breast feeding
  • Women of childbearing potential in whom pregnancy cannot be excluded or who are not using an adequate method of contraception
  • History of allergy and/or hypersensitivity to anti-coagulants/thrombolytic agents, especially heparin
  • History of immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura or other platelet disease, or laboratory evidence of anti-heparin antibodies
  • Uncontrolled or serious infection within the past 4 weeks
  • Patients who are unable to be compliant or to follow instructions given to them by clinic staff
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00130442

Locations
United States, Arizona
Arizona Cancer Centre
Tuscon, Arizona, United States, 85724
United States, Colorado
University of Colorado Health Science Centre
Denver, Colorado, United States, 80010-0510
United States, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6307
Australia, New South Wales
Sydney Cancer Centre, Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Westmead Institute for Cancer Research
Sydney, New South Wales, Australia, 2145
Australia, Queensland
Wesley Research Institute
Auchenflower, Queensland, Australia, 4066
Townsville Cancer Centre
Townsville, Queensland, Australia, 4814
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia, 5011
Australia, Victoria
Border Medical Oncology
Wodonga, Victoria, Australia, 3690
Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Royal Perth Hospital
Perth, Western Australia, Australia, 6001
Sponsors and Collaborators
Progen Pharmaceuticals
Investigators
Study Chair: Michael Millward, MD Sir Charles Gairdner Hospital
Principal Investigator: Anne Hamilton, PhD Sydney Cancer Centre
Principal Investigator: Damien Thomson, MD Princess Alexandra Hospital
  More Information

No publications provided

Responsible Party: Barbara Hicks; Regulatory & Pharmacovigilance Manager, Progen Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00130442     History of Changes
Obsolete Identifiers: NCT00128648
Other Study ID Numbers: PR88205
Study First Received: August 12, 2005
Last Updated: March 2, 2009
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Progen Pharmaceuticals:
phase II
metastatic melanoma
dacarbazine
combination
PI-88

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 26, 2014